ROI Financial Advisors LLC Sells 156 Shares of Johnson & Johnson (NYSE:JNJ)

ROI Financial Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,535 shares of the company’s stock after selling 156 shares during the quarter. ROI Financial Advisors LLC’s holdings in Johnson & Johnson were worth $249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in JNJ. China Universal Asset Management Co. Ltd. purchased a new position in shares of Johnson & Johnson in the first quarter worth about $765,000. Empowered Funds LLC increased its holdings in shares of Johnson & Johnson by 46.7% during the 1st quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock valued at $16,015,000 after purchasing an additional 32,244 shares in the last quarter. O Dell Group LLC boosted its holdings in Johnson & Johnson by 8.6% during the first quarter. O Dell Group LLC now owns 3,472 shares of the company’s stock worth $549,000 after buying an additional 276 shares in the last quarter. QRG Capital Management Inc. increased its holdings in Johnson & Johnson by 9.4% in the first quarter. QRG Capital Management Inc. now owns 453,858 shares of the company’s stock valued at $71,796,000 after buying an additional 38,961 shares in the last quarter. Finally, Qsemble Capital Management LP raised its position in shares of Johnson & Johnson by 275.0% in the first quarter. Qsemble Capital Management LP now owns 19,221 shares of the company’s stock worth $3,041,000 after acquiring an additional 14,096 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.4 %

Shares of JNJ opened at $153.28 on Thursday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The firm has a market cap of $369.04 billion, a P/E ratio of 22.18, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company’s 50-day moving average price is $162.10 and its 200 day moving average price is $156.01. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the previous year, the company earned $2.66 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is presently 71.78%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.00.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.